| General Information of Drug Metabolite (DM) (ID: DM019896) |
| DM Name |
LY-2603618 Metabolite H3
|
| Structure |
|
|
3D MOL is unavailable
|
2D MOL is unavailable
|
|
|
|
|
|
|
|
| Full List of Drug-Metabolizing Enzyme (DME) Related to This DM |
| DME(s) Producing This DM through Metabolism |
| DME Name |
DME ID |
Reactant |
Reaction |
Related Drug |
REF |
|
Cytochrome P450 2D6 (CYP2D6)
|
DME0009
|
| Oxidation - Hydroxylation |
LY-2603618
|
[1] |
|
Cytochrome P450 3A4 (CYP3A4)
|
DME0001
|
| Oxidation - Hydroxylation |
LY-2603618
|
[1] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Full List of Drug(s) That Produce This DM By Metabolism |
| LY-2603618 |
DR1846
|
Phase 2 |
Pancreatic cancer |
|
|
| References |
| 1 |
Disposition and metabolism of LY2603618, a Chk-1 inhibitor following intravenous administration in patients with advanced and/or metastatic solid tumors. Xenobiotica. 2014 Sep;44(9):827-41.
|
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.
